Neurocrine Biosciences, Inc. Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: Exceeded $800 million for the first time, marking a 44% year-over-year growth.

INGREZZA Sales: $657 million, up 20% year-over-year, driven by new patient additions. Adjusted growth, accounting for one less order week in Q1 2025, was approximately 11%.

Cranesity Sales: $153 million, benefiting from strong persistency and new patient enrollment.

Net Income: Approximately $200 million on both GAAP and non-GAAP bases, reflecting strong operational execution.

Guidance for INGREZZA: Reaffirmed at $2.7 to $2.8 billion for 2026.

2Strategic Updates and Business Highlights

Acquisition of Soleno Therapeutics: Expected to close in Q2 2026, aiming to enhance the company's portfolio, particularly for Prader-Willi syndrome.

Pipeline Development: Plans for six new phase 1 and four new phase 2 programs in 2026, with key data readouts anticipated in 2027 for multiple candidates.

Commercial Expansion: Continued investment in sales force and marketing initiatives, particularly for INGREZZA and Cranesity, to drive growth and improve patient access.

3Forward Guidance and Outlook

2026 Expectations: Anticipated strong performance across commercial products and pipeline advancements. The company is optimistic about sustaining growth momentum through the year.

Sales Force Impact: The expanded sales team is expected to enhance patient acquisition and retention, particularly for Cranesity.

4Bad News, Challenges, or Points of Concern

Gross-to-Net Pressure: Slight pressure observed in Q1 due to commercial copay resets.

Market Dynamics: Potential competitive pressures from changes in payer coverage for INGREZZA, particularly concerning the loss of preferred coverage for deuterated tetrabenazine in some plans.

Seasonality Effects: Historical seasonality in Q1 impacting sales, though the company managed it effectively this year.

5Notable Q&A Insights

Cranesity Growth: The launch is ahead of expectations, with steady new patient starts and high persistency rates. However, the majority of physicians have only treated one patient, indicating significant growth potential.

Pipeline Clarity: Phase 3 programs for major depressive disorder and schizophrenia are enrolling well, with readouts expected next year.

Market Penetration: Approximately 90% of TD patients are not receiving standard treatment, highlighting a substantial opportunity for INGREZZA.

Reauthorization Trends: High rates of reauthorization approvals for Cranesity, with no significant issues reported regarding insurance-related discontinuations. Overall, Neurocrine Biosciences demonstrated strong financial performance in Q1 2026, with a positive outlook driven by strategic initiatives and a robust pipeline, despite facing some competitive and market challenges.